Functionalized triblock copolymer vectors for the treatment of acute lymphoblastic leukemia

Robert C Deller, Paraskevi Diamanti, Gabriella Morrison, James Reilly, Benjamin C Ede, Robert Richardson, Kristian Le Vay, Andrew M Collins, Allison Blair*, Adam W Perriman

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

9 Citations (Scopus)
519 Downloads (Pure)


The chemotherapeutic Parthenolide is an exciting new candidate for the treatment of acute lymphoblastic leukemia, but like many other small-molecule drugs, it has low aqueous solubility. As a consequence, Parthenolide can only be administered clinically in the presence of harmful cosolvents. Accordingly, we describe the synthesis, characterization, and testing of a range of biocompatible triblock copolymer micelles as particle-based delivery vectors for the hydrophobic drug Parthenolide. The drug-loaded particles are produced via an emulsion-to-micelle transition method, and the effects of introducing anionic and cationic surface charges on stability, drug sequestration, biocompatibility, and efficacy are investigated. Significantly, we demonstrate high levels of efficacy in the organic solvent-free systems against human mesenchymal stem cells and primary T-acute lymphoblastic leukemia patient cells, highlighting the effectiveness of the delivery vectors for the treatment of acute lymphoblastic leukemia.

Original languageEnglish
Pages (from-to)722-732
Number of pages11
JournalMolecular Pharmaceutics
Issue number3
Early online date31 Jan 2017
Publication statusPublished - 6 Mar 2017

Structured keywords

  • BrisSynBio
  • Bristol BioDesign Institute


  • acute lymphoblastic leukemia (ALL)
  • micelle
  • nanoparticle
  • parthenolide
  • pluronic
  • poloxamer
  • Synthetic biology


Dive into the research topics of 'Functionalized triblock copolymer vectors for the treatment of acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this